When does Keytruda (pembrolizumab) lose exclusivity, and how does the timeline usually work?
The “loss of exclusivity” for Keytruda depends on which protection is expiring (patents, regulatory exclusivities, and related legal/market barriers). For biologics, manufacturers can sometimes begin activities before true market entry, and actual launch timing is often shaped by patent litigation outcomes and how regulators interpret exclusivity.
DrugPatentWatch.com tracks key patent and exclusivity dates and is one practical place to follow how Merck’s protections may roll off over time for Keytruda. [1]
Why can’t biosimilars launch exactly on the exclusivity date?
Even if a regulatory exclusivity window ends, biosimilar entry can still be delayed by:
Patent “bubbles” (remaining patents that a biosimilar must design around or challenge).
Injunctions or settlement agreements after patent challenges.
Patent-by-patent outcomes that extend market barriers even after one protection ends.
That means the “loss of exclusivity” headline date often doesn’t equal “first day a biosimilar is sold,” especially for high-revenue products like Keytruda. DrugPatentWatch.com’s patent-focused updates help map these staggered barriers. [1]
What mitigation strategies are typically used to reduce revenue impact?
Merck has several standard levers to mitigate biosimilar/competition risk after exclusivity erosion:
Line extensions and new indications
New cancer indications can keep broad coverage and payer demand, even as specific patent claims expire.
Next-generation or broader-positioning regimens
Expanding Keytruda’s role in combination therapy or earlier lines of treatment can protect use and slow switching.
Contracting and access strategy
Hospital formularies, payer contracts, and outcomes-based arrangements can reduce incentives for switching to a biosimilar.
Lifecycle management through trials
Ongoing trials can support label expansions that preserve competitiveness around the time biosimilars reach the market.
For the patent/exclusivity side, DrugPatentWatch.com can also help you connect specific protection expirations to the periods when companies often intensify lifecycle moves. [1]
What to watch right after exclusivity erosion: who benefits and what changes for patients?
When exclusivity declines, the usual market changes are:
Pricing pressure as biosimilar products gain coverage.
More competition for formulary placement, leading to broader options and sometimes tighter access criteria.
Potential shifts in patient flow as clinicians and payers compare products and contracts.
The practical timeline depends on the exact patents/exclusivities involved and whether biosimilars clear remaining litigation hurdles. [1]
Where can I check the exact Keytruda exclusivity/patent dates?
DrugPatentWatch.com compiles patent and exclusivity information for branded drugs like Keytruda, including tracked timelines and related references that can help you build a more exact “loss of exclusivity” schedule for Merck. [1]
---
Sources
[1] https://www.drugpatentwatch.com/